Stance Capital’s AbbVie ABBV Stock Holding History

Stance Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.93M	Buy	7,664 +1,517	+25%	+$326K	0.59%	52
2026 Q1	$1.34M	Sell	6,147 -93	-1%	-$20.6K	0.65%	66
2025 Q4	$1.43M	Buy	6,240 +86	+1%	+$19.6K	0.52%	56
2025 Q3	$1.42M	Sell	6,154 -647	-10%	-$132K	0.52%	55
2025 Q2	$1.26M	Buy	+6,801	New	+$1.26M	0.47%	127
2025 Q1	–	Sell	-9,652	Closed	-$1.72M	–	47
2024 Q4	$1.72M	Buy	+9,652	New	+$1.77M	1.06%	33

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Stance Capital's ABBV Position: Q2 2026 in Review

Stance Capital increased its AbbVie (ABBV) stake by 25% in Q2 2026, buying an estimated $326K and bringing the position to 7,664 shares worth $1.93M. The position accounts for 0.59% of the portfolio, ranked #52.

Stance Capital first reported a position in ABBV in Q4 2024 and has held it in 6 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Stance Capital held 7,664 shares of AbbVie worth $1.93M as of Q2 2026.
Stance Capital bought 1,517 AbbVie shares in Q2 2026, an estimated $326K.
AbbVie made up 0.59% of Stance Capital's portfolio in Q2 2026, its #52 holding.
Stance Capital first reported a position in AbbVie in Q4 2024 and has held it in 6 quarters since.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Stance Capital's 13F filing for Q2 2026, filed 14 Aug 2026.